Advertisement


Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone

2024 ASCO Annual Meeting

Advertisement

Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal therapy with docetaxel for hormone-sensitive disease compared with abiraterone plus prednisone alone (Abstract LBA5000).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Charter two was found positive for the primary outcome. At the time of the report of the results, there was a statistically significant difference of five months in terms of progression-free survival in favor of the patients who received cabazitaxel plus abirateron. For patients who received cabazitaxel and abirateron, the median progression-free survival was 14.9 months versus 9.9 months for the patients who received abirateron alone. So technically, the addition of cabazitaxel prolonged the progression-free survival by a little bit more than 50%. Even though charter two was found positive for the primary outcome, it is not a practice changing study. The main reason is because the landscape, the treatment landscape for metastatic castration-sensitive disease has changed, and there are not that many patients who are currently getting docetaxel plus androgen deprivation in the castration-sensitive setting. Nowadays, most patients receive either a double treatment, which includes treatment with abirateron or enzalutamide or any of the other second generation androgen receptor inhibitors. In cases that the patients receive treatment with docetaxel, that is usually in the context of a triplet therapy, which means that in addition to the docetaxel, they also receive treatment with abirateron or darolutamide or enzalutamide. That is the main reason that by the time these patients develop castration-resistant disease, they have already been exposed to a second generation androgen receptor inhibitor, which of course is like abirateron. As part of charter two, we did include two correlative studies that are in progress. The first one is the analysis of circulating tumor cells for splice variant seven, and the second one that we included in charter two was disease assessment using sodium fluoride PET imaging. This is ongoing work and hopefully we will be able to present those results in the future meeting. Also, as part of the study, we did collect plasma for patients who enrolled in the study, and we hope that we will be able to secure funding for some additional studies with those samples.

Related Videos

Gynecologic Cancers

Don S. Dizon, MD, on Ovarian and Other Extrarenal Clear Cell Carcinomas: Update on Nivolumab and Ipilimumab

Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).

Multiple Myeloma

Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib

Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lenalidomide, and dexamethasone deepened responses and increased the rate of measurable residual disease negativity vs isatuximab with lenalidomide and dexamethasone in patients with newly diagnosed transplant-ineligible multiple myeloma (Abstract 7501).

Kidney Cancer

Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial

Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as geneexpression signatures for tumorinduced proliferation, PDL1 status, or the mutation status of RCC driver genes.

Breast Cancer

Lisa A. Carey, MD, and Kevin Kalinsky, MD, on Advanced Breast Cancer: New Data on Abemaciclib and Fulvestrant From the postMONARCH Trial

Lisa A. Carey, MD, of University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Kevin Kalinsky, MD, of the Winship Cancer Institute of Emory University, discuss the first phase III findings showing a benefit of continued CDK4/6 inhibition with abemaciclib plus fulvestrant, following disease progression in patients with hormone receptor–positive, HER2-negative advanced breast cancer (LBA1001).

Clifford A. Hudis, MD: A Message From ASCO’s CEO

Clifford A. Hudis, MD, of the American Society of Clinical Oncology (ASCO), talks about the 2024 Annual Meeting, and a focus on the compassionate side of cancer care.

Advertisement

Advertisement




Advertisement